Clinical Study On Treatment Of Coronary Heart Disease With Stable Angina Pectoris By Qi - Tong Tong - Ming Soft Capsule

Purpose: To observe the Shenzhitongmai soft capsule for coronary heart disease stable angina pectoris(Qi deficiency blood stasis syndrome) of 90 patients the clinical curative effect and security。 Material and method:According to the inclusion criteria,90 patients of CHD angina(Qi deficiency blood stasis syndrome) were randomly divided into experimental group and control group 45 cases each.The experimental group was given Shenzhitongmai soft capsule 4 pills,there times a day,oral meal(0.6g/each piece).The control group was given Shenzhitongmai soft capsule mimetic,usage and dosage of the same experimental group. All the patients were treated with 4 weeks.To observe the change of symptoms of angina pectoris, consumption of nitroglycerin,efficacy of ECG and TCM symptoms for patients before and after treatment,and comparative safety indicators before and after taking the drug.Include:laboratory indexes, ECG and the possible of some adverse reactions occur.To analyze the data results according to SPSS17.0 statistic software, grading information is rank sum test,calculators information using chi-square test, measurement data using t-test. Results: 1.Evaluating curative effect: On the aspect of improving the symptoms of angina pectoris: the general effect rate of the experimental group is 84.09%,the general effect rate of the control group is 27.91%, the experimental group is better than the control group(P<0.05);Comparison the efficacy of ECG:the general effect rate of the experimental group is 56.82%,the general effect rate of the control group is 30.23%, the experimental group is better than the control group(P<0.05);On the aspect of improving the TCM symptoms : the general effect rate of the experimental group is 77.27%,the general effect rate of the control group is 27.91%, the experimental group is better than the control group(P<0.05);nitroglycerin stopped or decreased percentage:the general effect rate of the experimental group is 77.27%,the general effect rate of the control group is 23.26%, the experimental group is better than the control group(P<0.05). 2.Safety evaluation: the test process found no adverse reactions,indicating the Shenzhitongmai soft capsule has a good safety. Conclusion: 1. Shenzhitongmai soft capsules can effectively relieve symptoms of stable angina pectoris(Qi deficiency blood stasis syndrome) in patients with coronary heart disease, improve TCM symptoms, reduce the amount of nitroglycerin. 2. Shenzhitongmai soft capsule is an effective in the treatment of coronary heart disease stable angina(Qi deficiency blood stasis syndrome) of Traditional Chinese Medicine Patent Prescription. 3. Shenzhitongmai soft capsules treatment of coronary heart disease angina pectoris with better security.